Sparrow Pharmaceuticals
920 SW 6th Avenue
Suite 1200
Portland
Oregon
97204
United States
Website: http://www.sparrowpharma.com/
17 articles about Sparrow Pharmaceuticals
-
Sparrow Pharmaceuticals Doses First Patient in Phase 2 ACSpire Study of SPI-62 for Autonomous Cortisol Secretion
10/24/2023
Sparrow Pharmaceuticals today announced that the first patient has been dosed in the Phase 2 ACSpire study (NCT number: NCT05436639 ) of SPI-62.
-
Sparrow Pharmaceuticals Initiates Third Cohort in PROST!, Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica
9/12/2023
Sparrow Pharmaceuticals has expanded its PROST! Phase 2 clinical trial (NCT number: NCT05436652 ) of SPI-62 in combination with prednisolone for the treatment of polymyalgia rheumatica (PMR) to include a third cohort.
-
Sparrow Pharmaceuticals Announces First Patient Rolled-Over to Open-Label Extension of RESCUE, a Phase 2 Clinical Trial of SPI-62 for ACTH-Dependent Cushing’s Syndrome
8/16/2023
Sparrow Pharmaceuticals today announced the first patient has elected to enroll in the open-label extension (OLE) phase of the RESCUE trial, a phase 2 clinical trial of SPI-62.
-
Sparrow Pharmaceuticals to Present on HSD-1 Inhibitor SPI-62 at Endocrine Society 2023 Annual Conference
6/8/2023
Sparrow Pharmaceuticals will present the rationale that its lead candidate and HSD-1 inhibitor, SPI-62, is predicted to be associated with limited adrenal insufficiency risk in Cushing’s syndrome during a poster session at the Endocrine Society (ENDO) 2023 Annual Conference. The meeting will be held in-person from June 15-18, 2023 in Chicago, IL.
-
Sparrow Pharmaceuticals Presents ePoster on SPI-62 at the 25th European Congress of Endocrinology
5/13/2023
Sparrow Pharmaceuticals presented an ePoster on its lead candidate and HSD-1 inhibitor SPI-62 during a session, titled “Controlling intracellular cortisol: Can HSD-1 inhibition reduce Cushing’s syndrome morbidity and minimize adrenal insufficiency risk?” at the 25th European Congress of Endocrinology.
-
Sparrow Pharmaceuticals Expands Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica with Second Cohort
3/8/2023
Sparrow Pharmaceuticals has expanded its Phase 2 clinical trial (NCT number: NCT05436652 ) of prednisolone in combination with SPI-62 for the treatment of polymyalgia rheumatica (PMR) with the introduction of a second cohort to the study.
-
Sparrow Pharmaceuticals Presents Pharmacology Data on SPI-62 at American College of Rheumatology Convergence 2022
11/13/2022
Sparrow Pharmaceuticals presented pharmacology data during an online poster session on SPI-62, a HSD-1 inhibitor, at the American College of Rheumatology Convergence 2022 meeting.
-
Sparrow Pharmaceuticals Announces First Patient Dosed in RESCUE, a Phase 2 Clinical Trial of SPI-62 for Cushing’s Syndrome
9/28/2022
Sparrow Pharmaceuticals today announced that the first patient has been dosed in the RESCUE trial, a phase 2 clinical trial of SPI-62, a potent and selective HSD-1 inhibitor, for the treatment of ACTH-dependent Cushing’s syndrome.
-
Sparrow Pharmaceuticals Doses First Patient in Phase 2 Clinical Trial of SPI-62 with Prednisolone for Polymyalgia Rheumatica
9/9/2022
Sparrow Pharmaceuticals announced that the first patient has been dosed in a phase 2 clinical trial of prednisolone in combination with SPI-62, Sparrow’s potent and selective investigational HSD-1 inhibitor, for the treatment of polymyalgia rheumatica, a common autoimmune disease that causes widespread muscle pain and stiffness primarily in adults over 50.
-
Sparrow Pharmaceuticals Presents Clinical Trial Data Analyses on HSD-1 Inhibitor SPI-62 at the Endocrine Society (ENDO) 2022 Annual Meeting
6/14/2022
Sparrow Pharmaceuticals Presents Clinical Trial Data Analyses on HSD-1 Inhibitor SPI-62 at the Endocrine Society (ENDO) 2022 Annual Meeting.
-
Sparrow Pharmaceuticals to Present New Clinical Pharmacology Data on SPI-62 at the Endocrine Society (ENDO) 2022 Annual Conference
6/10/2022
Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today announced that it will present new clinical pharmacology data at the Endocrine Society (ENDO) 2022 Annual Conference on its candidate, SPI-62, an HSD-1 inhibitor.
-
Sparrow Pharmaceuticals Presents New Pharmacological Data on HSD-1 Inhibitor SPI-62 at the 2022 Annual European Congress of Rheumatology
6/4/2022
Sparrow Pharmaceuticals presented new animal model data during an in-person poster session titled, “Toward Safer Glucocorticoid Therapy of Polymyalgia Rheumatica” at the 2022 Annual European Congress of Rheumatology.
-
Sparrow Pharmaceuticals to Present New Pharmacology Data on SPI-62 at the 2022 Annual European Congress of Rheumatology
6/1/2022
Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies to address unmet needs in both endocrinology and rheumatology, today announced that it will present new pharmacology data at the 2022 Annual European Congress of Rheumatology (EULAR) on its lead candidate, SPI-62, an HSD-1 inhibitor.
-
Sparrow Pharmaceuticals Presents New Clinical Trial Data Analyses on HSD-1 Inhibitor SPI-62 at the 24th European Congress of Endocrinology
5/24/2022
Sparrow Pharmaceuticals today presented new pharmacological data during a poster session and a Rapid Communications session.
-
Sparrow Pharmaceuticals to Present New Clinical Pharmacology Data on SPI-62 at the 24th European Congress of Endocrinology
5/17/2022
Sparrow Pharmaceuticals, an emerging, clinical-stage biopharmaceutical company developing novel, targeted therapies for disorders of corticosteroid excess, today announced that it will present new clinical pharmacology data at the 24th European Congress of Endocrinology (ECE 2022) on its lead candidate, SPI-62, an HSD-1 inhibitor.
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
Sparrow Pharmaceuticals Announces FDA Clearance of IND for SPI-62 for the Treatment of Cushing’s Disease
12/13/2021
Sparrow Pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug Application (IND) that enables the company to proceed with initiating a phase 2 clinical trial to study SPI-62, a potent and selective investigational HSD-1 inhibitor, for the treatment of Cushing’s disease (CD).